RickMedChem

5.4K posts

RickMedChem banner
RickMedChem

RickMedChem

@RickMedChem

Part-time $XBI investor since 2020 (Long only). My opinions are my own and are not investment recommendations. I buy/sell without disclosures.

Katılım Nisan 2018
196 Takip Edilen3.1K Takipçiler
RickMedChem
RickMedChem@RickMedChem·
Personally a little bit worried about $CMPS (I was long them until recently). Why did $LLY choose $ATAI over $CMPS despite the fact that the latter is way ahead?
English
0
0
2
152
RickMedChem retweetledi
BioHope Pawcio
BioHope Pawcio@pawcio2009·
Haha type in “Erling Haaland” in google search bar 😂
English
1
1
7
1.8K
RickMedChem retweetledi
Kevin Jacobs
Kevin Jacobs@kevinjaybe·
From Belgium with love ❤️ Cya!
English
0
1
1
545
RickMedChem retweetledi
Wall St Engine
Wall St Engine@wallstengine·
Samsung Electronics prelim Q2 operating profit surged 19x YoY to ~$58.4B, above $55.3B consensus, on AI memory demand. However, prelim Q2 revenue came in slightly shy at ~$111.8B, vs $113.1B consensus, though still up 129% YoY.
Wall St Engine tweet media
English
26
61
395
66.9K
RickMedChem
RickMedChem@RickMedChem·
$CRNX Congrats longs! What a nice premium! I was long $CRNX a few months ago actually... Got bored and looked for something else 😭
English
1
0
9
1K
RickMedChem
RickMedChem@RickMedChem·
@AppleHelix Novartis buying an ADC company? Interesting. I thought they were all in radiopharmaceuticals.
English
3
0
4
469
Jing Liang 🇺🇦
Jing Liang 🇺🇦@AppleHelix·
Another ADC acquisition. This time novel payload (N-Myristoyltransferase inhibitor) $NVS to acquire Myricx (UK based) for $1.1B u/f + $0.4B backend. Seeded by Sofinnova Partners (Maina Bhaman) and Brandon Capital (Jonathan Tobin). Series A co-led by Abingworth (Jayson Punwani) and Novo Holdings (Michael Bauer) $114m series A was exactly 2 years ago. So this must be a very good return. businesswire.com/news/home/2026…
English
3
6
41
20.2K
RickMedChem
RickMedChem@RickMedChem·
Football is arguably the best sport in the world. One that can gather all the people on this planet.
English
0
0
2
763
RickMedChem
RickMedChem@RickMedChem·
@Sanctuary_Bio People indebting have always been a problem, but the bigger issue IMO these days are those 2x, 3x leveraged ETFs centered around Samsung of SK Hynix. These are sucking all the money and exacerbate the instability of the market.
English
1
0
0
388
RickMedChem
RickMedChem@RickMedChem·
@Sanctuary_Bio Very rewarding P&L if at the start of the year SK hynix, Samsung Electronics, Samsung Electrics or SK Square made the majority of long positions, like very high double digit YTD return. Not profitable actually if you don't them in your portfolio. Very frustruating.
English
1
0
1
527
WC
WC@Sanctuary_Bio·
I'm genuinely curious what the average P&L of Korea-based investors are this year given that the KOSPI is up like 81% ytd, but half of it is in SK Hynix and Samsung Electronics, and the insane leverage being used is highly documented.
English
6
0
14
4K
Jonathan Faison
Jonathan Faison@jfais20·
Perhaps another relevant question... What do you think is another $ABVX - type setup where there's a disconnect between market perception & thesis progression?
Jonathan Faison@jfais20

$ABVX - no matter what side of the debate you were on, should be genuinely happy for longs IMO More wins in biotech = better for the sector $XBI Perhaps a key takeaway is that @A_May_MD, @seedy19tron, @Biohazard3737 & others simply followed thesis progression & held patiently (pulled a Jose) We can all learn from that...

English
18
1
36
23.4K
RickMedChem retweetledi
Banana Oncology
Banana Oncology@Banana_Oncology·
Regular reminder: $PSNL market cap is currently only 1/29.7 of $NTRA market cap
English
3
4
44
7K
RickMedChem retweetledi
Adam Feuerstein ✡️
Adam Feuerstein ✡️@adamfeuerstein·
Biotech is booming but everyone seems miserable with the $ABVX flu.
English
24
1
99
36.6K
RickMedChem
RickMedChem@RickMedChem·
Expect the Korean stock market to look like a gamling place today here in Asia.
Wall St Engine@wallstengine

MICRON $MU Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $41.46B (Est. $35.5B) 🟢 🔹 Adj. EPS: $25.11 (Est. $20.4) 🟢 🔹 Adj. Gross Margin: 84.9% (Est. 81.8%) 🟢 Q4 Guide: 🔹 Revenue: $50.0B ± $1.0B (Est. $43.4B) 🟢 🔹 Adj. EPS: $31.00 ± $1.00 (Est. $24.3) 🟢 🔹 Gross Margin: 86% (Est. 83%) 🟢 🔹 OpEx: Approximately $1.65B Q3 Segment Revenue: 🔹 Cloud Memory: $13.76B (Est. $10.69B) 🟢 🔹 Core Data Center: $11.52B (Est. $6.8B) 🟢 🔹 Mobile & Client: $11.52B 🔹 Automotive & Embedded: $4.63B (Est. $3.51B) 🟢 Other Metrics: 🔹 HBM4: In high-volume shipments for lead customer platform 🔹 HBM4E: Volume production expected in calendar 2027 🔹 G9-based PCIe Gen6 high-performance SSD: In high-volume production 🔹 High-capacity 245TB QLC SSD: Shipments commenced Financials: 🔹 Adj. Gross Margin: $35.199B 🔹 Adj. Operating Income: $33.681B 🔹 Adj. OpEx: $1.518B 🔹 Investments in CapEx, net: $7.1B 🔹 Cash, marketable investments, and restricted cash: $30.2B 🔹 Operating Cash Flow: $25.39B 🔹 Adjusted FCF: $18.3B Capital Return: 🔹 Dividend: $0.15/share payable July 21, 2026 to shareholders of record as of July 6, 2026 Commentary: 🔸 “Micron’s record fiscal Q3 financial results and even stronger outlook for Q4 reflect the strategic value of memory in the AI era.” 🔸 “Micron is investing at record levels in technology, products and supply to address our customers’ rapidly growing demand.” 🔸 “We believe our multi-year Strategic Customer Agreements will significantly enhance the durability and predictability of Micron’s strong financial performance.” 🔸 Expects tight conditions to persist beyond calendar 2027 due to AI-driven demand across all segments

English
0
0
1
877
RickMedChem retweetledi
Adam May
Adam May@A_May_MD·
1) No, I do not know what is going on. 2) Yes, it is my largest position. 3) No, I am not selling. 4) No, I have not seen a short report, but if there is one, I look forward to absolutely tearing it apart. $ABVX
English
33
6
410
47.6K
RickMedChem retweetledi
Marc the lemming
Marc the lemming@threadanddoc·
i just got cancer
English
6
2
39
7.6K